It is thus attractive that CRank identified minaprine as a member of a community of primarily cholinesterase inhibitors, which suggests minaprine’s potential for drug repurposing for Alzheimer’s disease. This evidence concerns the gene BCHE and early-onset autosomal dominant Alzheimer disease.